# Omentin-1 Level and Carotid Intimal Thickening in Patients with Fatty Liver Disease and Diabetes Type 2

Thesis
Submitted for partial fulfillment of MD degree in
Internal Medicine

Ebrahim Eid Basyouny Mohamed M.B, B.Ch, M.Sc.

#### Under supervision of

#### Prof. Dr. Mohamed Ali Marei Makhlouf

Professor of Internal Medicine Faculty of Medicine, Ain Shams University

### Prof. Dr. Esam Farid Mohamed El Mahdy

Professor of Internal Medicine Faculty of Medicine, Ain Shams University

#### **Prof. Dr. Amir Helmy Samy**

Professor of Internal Medicine Faculty of Medicine, Ain Shams University

#### Asst. Prof. Dr. Khaled Amr Zaky

Assistant Professor of Internal Medicine Faculty of medicine, Ain Shams University

Faculty of Medicine Ain Shams University 2018



## FIRST AND FOREMOST THANKS TO ALLAH, THE MOST MERCIFUL

I would like to express my deep appreciation to **Prof. Dr. Mohamed Ali Maraey Makhlouf** and **Prof. Dr. Esam Farid Mohamed El Mahdy,** Professors of Internal Medicine, Faculty of Medicine, Ain Shams University, for their meticulous supervision, kind help, valuable support, I am deeply affected by their noble.

Moreover I would like to express my sincere and deepest gratitude to **Prof. Dr. Amir Helmy Samy**, Professors of Internal Medicine, Faculty of Medicine, Ain Shams University and **Asst. Prof. Dr. Khaled Amr Zaki**, Assistant Professor of Internal Medicine, Faculty of Medicine, Ain Shams University, for their supervision, help, valuable support and guidance. I am deeply affected by their character, perfection, care and consideration.

Many thanks to **Prof Dr. Moustafa Rezk**, Professor of clinical pathology, Alex Univ and **Dr. Wael Abdelhamed**, specialist of Radiology, Alex Police Hospital, for their participation in the practical part of this work.

Many thanks to my professors and colleagues in Internal Medicine department.

Many thanks to my Father and mother for their great support to complete this work.

Many thanks to my Wife for her support, help and continuo's encouragement through the whole research.

Ebrahim Eid Basyouny Mohamed

## **LIST OF CONTENTS**

		Page
ACKN	NOWLEDGMENT	····
LIST	OF ABBREVIATIONS	i
LIST	OF TABLES	iii
LIST	OF FIGURES	iv
I.	INTRODUCTION	1
II.	AIM OF THE WORK	4
III.	REVIEW OF LITERATURE	5
	Chapter I: Non Alcoholic Fatty Liver Disease	5
	Chapter II: Diabetes Mellitus	28
	Chapter III: Obesity	72
	Chapter IV: Adipokines in Obesity and Diabetes	79
IV.	SUBJECTS AND METHODS	90
V.	RESULTS	98
VI.	DISCUSSION	141
VII.	SUMMARY	154
VIII.	CONCLUSION	158
IX.	RECOMMENDATIONS	160
<b>X.</b>	REFERENCES	161
	ARABIC SUMMARY	

#### **List of Abbreviations**

**ABI** : Ankle/brachial index

**ACEI** : Angiotensin converting enzyme inhibitor

**ADA** : American diabetes association **AGE** : Advanced glycation end products

AMI : Acute myocardial infarction
ARB : Angiotensin receptor blocker

**BMI** : Body mass index

CAD : Coronary artery disease
CLD : Chronic liver disease

**COX** : Cyclo-oxegenase enzyme

**CRP** : C-reactive protein

CVD : Cardiovascular disease
CVS : Cerebrovascular stroke

**DM** : Diabetes mellitus

DNA : Deoxyribonucleic acid
ELF : Enhanced liver fibrosis
ESRD : End stage renal disease
FBG : Fasting blood glucose
FXR : Farnesoid X receptor

**GAD** : Glutamic acid decarboxylase enzyme

**GDM** : Gestational diabetes mellitus

**HbA1C** : Hemoglobin A1C

HDL : High density lipoproteinHLA : Human leukocyte antigenHPL : Human placental lactogen

HR : Heart rateHTN : HypertensionHS : Hepatic steatosis

**ICAM-1** : Intercellular cell adhesion molecule -1

IFG : Impaired fasting glucoseIGT : Impaired glucose tolerance

**IDF** : International Diabetes Federation

**IHD** : Ischemic heart disease

IL-6 : Interleukin-6

#### List of Abbreviations (Cont.)

**IMT** : Intima media thickness

**LADA** : Latent autoimmune diabetes of adults

**LDL** : Low Density lipoprotein

MAPK : Mitogen-activated protein kinase

MI : Myocardial infarction
MMPs : Matrix metalloproteinase

MODY : Maturity-onset diabetes mellitusMRE : Magnetic resonance elastography

**mRNA** : Messenger ribonucleic acid

**NAFLD** : Non-alcoholic fatty liver disease

**NFS** : NAFLD fibrosis score

NIDDM : Non-insulin dependant diabetes mellitus

NO : Nitric oxide

**NPDR** : Non-progressive diabetes retinopathy

**OGTT** : Oral glucose tolerance test

**OSAS** : Obstructive sleep apnea syndrome

OCA : Obeticholic acid

PAD : Peripheral arterial disease PCOS : Polycystic ovary syndrome

**PDR** : Progressive diabetes retinopathy

**PPARS** : Peroxisome proliferator-activated receptors

TNF-α : Tumor necrosis factor-αTIA : Transient ischemic attack

**TZDs** : Thiazolidinedione's

**UKPDS** : United Kingdom prospective diabetes study

VCAM-1 : Vascular cell adhesion molecule -1 VEGD : Vascular endothelial growth factor

**WAT** : White adipose tissue

**WHO** : World health organization

## **List of Tables**

Table	Title			
(1)	Classification of obesity according to BMI values for Caucasians	72		
(2)	Comparison between the three studied groups according to demographic data	99		
(3)	Comparison between the three studied groups according to Thyroid Function	101		
(4)	Comparison between the three studied groups according to liver function	102		
(5)	Comparison between the three studied groups according to Diabetes profile	104		
(6)	Comparison between the three studied groups according to lipid profile	105		
(7)	Comparison between the three studied groups according to renal function	110		
(8)	Comparison between the three studied groups according to serum omentin	111		
(9)	Comparison between the three studied groups according to IMT	112		
(10)	Correlation between different parameters in total sample (n= 90)			
(11)	Correlation between different parameters in NAFLD group (n= 30)			
(12)	Correlation between different parameters in diabetic group (n= 30)	131		

Table	Title	Page
(13)	Diagnostic performance of serum omentin level in prediction of NAFLD	137
(14)	Diagnostic performance of Carotid-IMT in prediction of NAFLD	138
(15)	Relation between BMI with serum omentin and carotid doppler in NAFLD group (n= 30)	139

## **List of Figures**

Figure	Title				
(1)	Pathologic processes in NAFLD and potential therapeutic targets	22			
(2)	Geographical distribution of diabetes prevalence worldwide	29			
(3)	Disorders of glycemia: etiologic types and stages	37			
(4)	Human omentin ELISA standard curve	97			
(5)	Comparison between the three studied groups according to BMI (kg/m2)	100			
(6)	Comparison between the three studied groups according to Waist (cm)	100			
(7)	Comparison between the three studied groups according to PPBS (mg/dl)	105			
(8)	Comparison between the three studied groups according to HAC 1 (%)	105			
(9)	Comparison between the three studied groups according to FBS (mg/dl)	106			
(10)	Comparison between the three studied groups according to lipid profile	109			
(11)	Comparison between the three studied groups according to serum omentin	111			
(12)	Comparison between the three studied groups according to IMT	113			

Figure	Title	Page
(13)	Correlation between serum omentin (ng/ml) with BMI (kg/m2) in total sample	115
(14)	Correlation between serum omentin (ng/ml.) with waist (cm) in total sample	116
(15)	Correlation between serum omentin (ng/ml.) with PPBS in total sample	116
(16)	Correlation between serum omentin (ng/ml.) with HbA1C(%) in total sample	117
(17)	Correlation between serum omentin (ng/ml.) with LDL (mg/dl) in total sample	117
(18)	Correlation between Carotid Doppler (cm) with BMI (kg/m2) in total sample	118
(19)	Correlation between Carotid Doppler (cm) with waist (cm) in total sample	119
(20)	Correlation between Carotid Doppler (cm) with PPBS in total sample	120
(21)	Correlation between Carotid Doppler (cm) with HbA1C (%) in total sample	120
(22)	Correlation between Carotid Doppler (cm) with LDL (mg/dl) in total sample	120
(23)	Correlation between Waist (cm) with BMI (kg/m2) in total sample	121
(24)	Correlation between FBG (mg/dl) with BMI (kg/m2) in total sample	122

Figure	Title	Page
(25)	Correlation between LDL (mg/dl) with BMI (kg/m2) in total sample	122
(26)	Correlation between TG (mg/dl) with BMI (kg/m2) in total sample.	123
(27)	Correlation between FBS (mg/dl) with waist (cm) in total sample	124
(28)	Correlation between LDL (mg/dl) with waist (cm) in total sample	125
(29)	Correlation between TG (mg/dl) with waist (cm) in total sample	125
(30)	Correlation between Serum omentin (ng/ml.) with FBS (mg/dl) in NAFLD group	127
(31)	Correlation between Carotid Doppler with BMI (kg/m2) in NAFLD group	128
(32)	Correlation between Carotid Doppler with Waist circumference (cm) in NAFLD group	128
(33)	Correlation between Carotid Doppler with PPBS in NAFLD group	129
(34)	Correlation between Carotid Doppler with FBS (mg/dl) in NAFLD group	129
(35)	Correlation between Carotid Doppler with HDL (mg/dl) in NAFLD group	131
(36)	Correlation between Carotid Doppler with BMI (kg/m2) in diabetic group	132

Figure	Title	Page
(37)	Correlation between Carotid Doppler with Waist circumference (cm) in diabetic group	133
(38)	Correlation between Carotid Doppler with PPBS in diabetic group	133
(39)	Correlation between Carotid Doppler with HA1C (%) in diabetic group	134
(40)	Correlation between Carotid Doppler with FBS (mg/dl) in diabetic group	134
(41)	Correlation between Carotid Doppler with LDL (mg/dl) in diabetic group	135
(42)	Correlation between Carotid Doppler with TG (mg/dl) in diabetic group	135
(43)	Correlation between Carotid Doppler with TC (mg/dl) in diabetic group	136
(44)	ROC curve for serum omentin to predict NAFLD vs normal	137
(45)	ROC curve for Carotid doppler to predict NAFLD vs normal	138
(46)	Relation between BMI with serum Omentin in NAFLD group	140
(47)	Relation between BMI with Carotid doppler in NAFLD group	140

#### **Abstract**

**Introduction:** Adipokines are the fat-derived hormones released from adipose tissue. Many are associated with insulin resistance, obesity and metabolic syndrome. Adipokines can be both pro-inflammation and anti-inflammation factors

**Aim of the Work:** The primary aim of this work is to detect the level of Omentin-1 marker and carotid intimal media thickness in patients with fatty liver disease and type 2 diabetes

**Subjects:** This study included 90 patients recruited from the department of Internal Medicine of Alex Police Hospital and the outpatient clinic

**RESULTS:** The study was performed on 90 subjects divided into 3 groups, 30 of them were diabeties type 2, 30 have NAFLD and 30 were healthy subjects as control group

**Discussion:** Epidemiological studies have showed a significant rise in the prevalence of diabetes particularly type 2 diabetes worldwide resulting in an increased burden on individuals and health care system. In 2012, an estimated 347 million people have type 2 diabetes

**Summary:** Non-alcoholic fatty liver disease (NAFLD) is a well-established hepatic manifestation of the metabolic syndrome and is one of the most common causes of chronic liver disease

**Conclusion:** Omentin-1 level is significantly lower in subjects with diabetes and NAFLD in comparison with control group

**Recommendations:** Further studies with larger samples are needed to consolidate the relation between omentin-1 and carotid IMT in NAFLD and Diabetic patients

**Key Word:** Ankle/brachial index, Chronic liver disease, Enhanced liver fibrosis

#### Introduction

Adipokines are the fat-derived hormones released from adipose tissue. Many are associated with insulin resistance, obesity and metabolic syndrome. Adipokines can be both proinflammation and anti-inflammation factors (Maury and Brichard, 2010).

Omentin-1 is adipokine that is primarily secreted by stromal vascular cells in visceral adipose tissue, and is expressed to a lesser extent in the heart, lung, and placenta (**Tan et al., 2010**).

Omentin-1 is a beneficial adipokine that enhances insulinstimulated glucose uptake and triggers Akt signaling, which mediates downstream effects such as glucose metabolism (**Auguet** et al., 2011).

Along these lines, dysregulation of omentin-1 secretion is thought to play a role in the pathophysiology of insulin resistance, inflammation, endothelial dysfunction, and cardiovascular disease (Pan et al., 2010).

In clinical studies, circulating omentin-1 concentrations have been shown to be decreased in patients with obesity, impaired glucose regulation, polycystic ovary syndrome, type 1 diabetes, and type 2 diabetes (**Choi et al., 2011**).

Given these clinical associations, omentin-1 has garnered attention as a possible contributor to the pathogenesis of the metabolic syndrome (Yan et al., 2011).

Plasma omentin-1 levels inversely correlate with body mass index (BMI), fat mass, and fasting plasma insulin, and positively